П

FORM 4

obligations may continue. See Instruction 1(b).

Check this box if no longer subject to Section 16. Form 4 or Form 5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| l | | JVAL | | | | | | |
|---|--------------------------|-----------|--|--|--|--|--|--|
| | OMB Number: | 3235-0287 | | | | | | |
| | Estimated average burden | | | | | | | |
| | hours per response: | 0.5 | | | | | | |

Ī

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| 1. Name and Add <u>Khayal Tar</u> | dress of Reporting <u>ner I</u> | Person* | 2. Issuer Name and Ticker or Trading Symbol <u>TransMedics Group, Inc.</u> [TMDX] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner | | | | | | | |
|--|------------------------------------|----------------------|--|---|--|--|--|--|--|--|--|
| (Last) C/O TRANS | (First) MEDICS GROU | (Middle) JP, INC. | 3. Date of Earliest Transaction (Month/Day/Year) 02/14/2024 | X Officer (give title Other (specify below) below) Chief Commercial Officer | | | | | | | |
| 200 MINUTE (Street) ANDOVER | 200 MINUTEMAN ROAD (Street) | | 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | | | |
| (City) | (State) | (Zip) | Rule 10b5-1(c) Transaction Indication X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | |

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | | | | 5. Amount of Securities Beneficially Owned Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership |
|---------------------------------|--|---|---|---|--------|---------------|----------------------------|---|---|--|
| | | | Code | v | Amount | (A) or (D) | Price | Reported Transaction(s) (Instr. 3 and 4) | | (Instr. 4) |
| Common Stock | 02/14/2024 | | M ⁽¹⁾ | | 3,050 | Α | \$16 | 17,425 | D | |
| Common Stock | 02/14/2024 | | S ⁽¹⁾ | | 3,050 | D | \$90.03(2) | 14,375 | D | |
| Common Stock | 02/15/2024 | | M ⁽¹⁾ | | 776 | A | \$16 | 15,151 | D | |
| Common Stock | 02/15/2024 | | S ⁽¹⁾ | | 776 | D | \$90 ⁽³⁾ | 14,375(4) | D | |
| Common Stock | | | | | | | | 14,776 | I | By the Khayal Family 2021 Irrevocable Trust |
| Common Stock | | | | | | | | 11,051 | Ι | By the Tamer Ibrahim Ahmed Khayal Trust |

| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | |
|--|---|--|---|---|---|---|-------|--|--------------------|--|--|---|--|--|--|
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Stock Option (Right to Buy) | \$16 | 02/14/2024 | | M ⁽¹⁾ | | | 3,050 | (5) | 05/01/2029 | Common Stock | 3,050 | \$0.00 | 1,920 | D | |
| Stock Option (Right to Buy) | \$16 | 02/15/2024 | | M ⁽¹⁾ | | | 776 | (5) | 05/01/2029 | Common Stock | 776 | \$0.00 | 1,144 | D | |

Explanation of Responses:

1. The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

2. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$90.00 to \$90.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. 3. The price reported is a weighted average price. These shares were sold in multiple transactions ranging from \$90.00 to \$90.005, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

4. Includes 13,075 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The option is fully vested.



Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.